or earlier we spoke to says he's with the european public health alliance, and is a board member of the european medicines agency, which is dealing with modern as request for authorization. here's his assessments. we seen in recent weeks, a lot of these press releases from several pharmaceutical companies. we've seen candidates, but pharmaceutical companies press release is not necessarily science. it can be marketing but is not science. so where this very critical point right now, where the regulators, for instance, the european medicines agency in europe, needs to look at all the data and come to its own conclusions on whether and not and when to authorize these products and to provide these at the ground for these, vaccine candidate with a condition of marketing authorization for the u.s., it's up to the food and drug administration, the f.d.a. . so there they have different procedures and we see when the green light, we come from the e.u. made for the for europe. doesn't it? the zip tool assessments do not necessarily need to be aligned. i would say at this stage, we have on one han

so with a european public health alliance, and as a member or a board member of the european medicines agency, aid, which is dealing with modernise requests for authorization, he has his assessment seen in recent weeks. a lot of these press releases from several pharmaceutical companies. we've seen candidates, but pharmaceutical companies press release is not necessarily science. it can be marketing but is not science. so where this very critical point right now, where the regulators, for instance, the european medicines agency in europe, needs to look at all that they've got up and come to its own conclusions on whether and not and when to authorize these projects and to provide the basis of the grounds of these vaccine candidate with, a condition of marketing authorization for the u.s., it's up to the food and drug administration, the f.d.a. . so there they have different procedures and we will see when the green light we come from, the e.u. made for the for europe doesn't have the zip to hold assessments do not necessarily need to be aligned. i would say this stage we have on one ha

and earlier we spoke seattle snaps, it stays with a european public health alliance and is a board member of the european medicines agency, which is dealing with letter in his request for authorization. he has his assessments seen in recent weeks. a lot of these press releases from several pharmaceutical companies. we've seen candidates, but pharmaceutical companies press release is not necessarily science. it can be marketing, but is not science. so where that is very critical point right now, where the regulators, for instance, the european medicines agency in europe, needs to look at all that they've got up and come to its own conclusions on whether and not and when to authorize these products and to provide decent to the ground these vaccine candidate with a condition of marketing authorization for the u.s. . it's up to the food and drug administration, the f.d.a. . so there they have different procedures and we see when the green light, we come from the e.u. made for the for europe. doesn't these it tool assessments do not necessarily need to be aligned. i would say at this stage, we